AnaptysBio
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 75.0m | 63.2m | 10.3m | 17.2m | 32.0m | 31.7m | 35.8m |
| % growth | 838 % | (16 %) | (84 %) | 67 % | 86 % | (1 %) | 13 % |
| EBITDA | (19.4m) | (56.3m) | (108m) | (136m) | (163m) | (177m) | (144m) |
| % EBITDA margin | (26 %) | (89 %) | (1046 %) | (792 %) | (510 %) | (558 %) | (403 %) |
| Profit | (19.9m) | (57.8m) | (129m) | (164m) | (189m) | (226m) | (264m) |
| % profit margin | (27 %) | (91 %) | (1251 %) | (954 %) | (592 %) | (714 %) | (737 %) |
| EV / revenue | 2.6x | 6.5x | 42.8x | 8.8x | 25.1x | 26.0x | 32.1x |
| EV / EBITDA | -10.0x | -7.3x | -4.1x | -1.1x | -4.9x | -4.7x | -8.0x |
| R&D budget | 80.0m | 98.5m | 88.8m | 132m | - | - | - |
| R&D % of revenue | 107 % | 156 % | 863 % | 771 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$2.0m | Series A | ||
$33.9m | Series B | ||
| N/A | $8.0m | Early VC | |
| N/A | $2.0m | Debt | |
$40.0m | Series D | ||
| N/A | N/A | IPO | |
* | $100m | Post IPO Equity | |
| Total Funding | €76.3m | ||
Recent News about AnaptysBio
EditAnaptysBio is a clinical-stage biotechnology company specializing in the development of therapeutic antibody product candidates aimed at addressing unmet medical needs in the field of inflammation. The company operates primarily in the biopharmaceutical sector, focusing on innovative treatments that target immune system disorders. AnaptysBio serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies, who are in need of advanced therapeutic solutions for inflammatory diseases.
The company's business model revolves around the research, development, and commercialization of its antibody candidates. AnaptysBio generates revenue through partnerships, licensing agreements, and potential future sales of its proprietary therapies. The company is currently advancing several product candidates through clinical trials, with a strong emphasis on first-in-class treatments that offer novel mechanisms of action.
AnaptysBio's market is characterized by high growth potential, driven by the increasing prevalence of inflammatory diseases and the ongoing demand for more effective and targeted therapies. The company aims to leverage its scientific expertise and robust pipeline to capture a significant share of this expanding market.
Keywords: therapeutic antibodies, inflammation, clinical-stage, biotechnology, immune disorders, biopharmaceutical, innovative treatments, research, development, commercialization.